All Stories

  1. Body mass index and clinical outcomes in individuals with major depressive disorder: Findings from the GSRD European Multicenter Database

    Article • Journal of Affective Disorders, August 2023, Elsevier

    Giuseppe Fanelli

  2. Real-world characteristics of European patients receiving SNRIs as first-line treatment for major depressive disorder

    Article • Journal of Affective Disorders, July 2023, Elsevier

    Giuseppe Fanelli

  3. Age or age of onset: which is the best criterion to classify late-life depression?

    Article • International Clinical Psychopharmacology, March 2023, Wolters Kluwer Health

    Giuseppe Fanelli

  4. Clinical correlates and prognostic implications of severe suicidal ideation in major depressive disorder

    Article • International Clinical Psychopharmacology, February 2023, Wolters Kluwer Health

    Giuseppe Fanelli

  5. Hyperthyroidism and depression: a clinical case of atypical thyrotoxicosis manifestation

    Article • International Clinical Psychopharmacology, February 2023, Wolters Kluwer Health

    Giuseppe Fanelli

  6. Melancholic features and typical neurovegetative symptoms of major depressive disorder show specific polygenic patterns

    Article • Journal of Affective Disorders, January 2023, Elsevier

    Giuseppe Fanelli

  7. The link between cognition and somatic conditions related to insulin resistance in the UK Biobank study cohort: a systematic review

    Article • Neuroscience & Biobehavioral Reviews, December 2022, Elsevier

    Fernando Fernandez-Aranda, Giuseppe Fanelli

  8. LOCAL PATTERNS OF SHARED GENETICS AND A GENETIC LATENT FACTOR OF INSULIN RESISTANCE AND NEUROPSYCHIATRIC MULTIMORBIDITY

    Article • European Neuropsychopharmacology, October 2022, Elsevier

    Giuseppe Fanelli

  9. Patterns of antipsychotic prescription and accelerometer-based physical activity levels in people with schizophrenia spectrum disorders: a multicenter, prospective study

    Article • International Clinical Psychopharmacology, September 2022, Wolters Kluwer Health

    Giuseppe Fanelli

  10. The sociodemographic and clinical phenotype of European patients with major depressive disorder undergoing first-line antidepressant treatment with NaSSAs

    Article • Journal of Affective Disorders, September 2022, Elsevier

    Giuseppe Fanelli

  11. Temporally ordered associations between type 2 diabetes and brain disorders – a Danish register-based cohort study

    Article • BMC Psychiatry, August 2022, Springer Science + Business Media

    Fernando Fernandez-Aranda, Giuseppe Fanelli

  12. The Italian version of the Brief Assessment of Cognition in Affective Disorders: performance of patients with bipolar disorder and healthy controls

    Article • Comprehensive Psychiatry, August 2022, Elsevier

    Giuseppe Fanelli

  13. Clinical correlates and prognostic impact of binge-eating symptoms in major depressive disorder

    Article • International Clinical Psychopharmacology, July 2022, Wolters Kluwer Health

    Giuseppe Fanelli

  14. The dilemma of polypharmacy in psychosis: is it worth combining partial and full dopamine modulation?

    Article • International Clinical Psychopharmacology, July 2022, Wolters Kluwer Health

    Giuseppe Fanelli

  15. Machine Learning Prediction of Comorbid Substance Use Disorders among People with Bipolar Disorder

    Article • Journal of Clinical Medicine, July 2022, MDPI AG

    Giuseppe Fanelli

  16. Depression, antidepressants, and insulin resistance: which link?

    Article • European Neuropsychopharmacology, July 2022, Elsevier

    Giuseppe Fanelli

  17. The U-shaped relationship between parental age and the risk of bipolar disorder in the offspring: A systematic review and meta-analysis

    Article • European Neuropsychopharmacology, July 2022, Elsevier

    Giuseppe Fanelli

  18. Epigenetic Basis of Psychiatric Disorders: A Narrative Review

    Article • CNS & Neurological Disorders - Drug Targets, May 2022, Bentham Science Publishers

    Giuseppe Fanelli

  19. Evidence on sociodemographic and clinical correlates of antidepressant combination or augmentation with second-generation antipsychotics in major depressive disorder

    Article • Progress in Neuro-Psychopharmacology and Biological Psychiatry, March 2022, Elsevier

    Giuseppe Fanelli

  20. Polygenic risk scores for neuropsychiatric, inflammatory, and cardio‐metabolic traits highlight possible genetic overlap with suicide attempt and treatment‐emergent suicidal ideation

    Article • American Journal of Medical Genetics Part B Neuropsychiatric Genetics, February 2022, Wiley

    Giuseppe Fanelli

  21. Obsessive-compulsive symptoms in major depressive disorder correlate with clinical severity and mixed features

    Article • International Clinical Psychopharmacology, February 2022, Wolters Kluwer Health

    Giuseppe Fanelli

  22. Insulinopathies of the brain? Genetic overlap between somatic insulin-related and neuropsychiatric disorders

    Article • Translational Psychiatry, February 2022, Springer Science + Business Media

    Giuseppe Fanelli

  23. A meta-analysis of polygenic risk scores for mood disorders, neuroticism, and schizophrenia in antidepressant response

    Article • European Neuropsychopharmacology, February 2022, Elsevier

    Giuseppe Fanelli

  24. The sociodemographic and clinical profile of patients with major depressive disorder receiving SSRIs as first-line antidepressant treatment in European countries

    Article • European Archives of Psychiatry and Clinical Neuroscience, January 2022, Springer Science + Business Media

    Giuseppe Fanelli

  25. Social withdrawal as a trans-diagnostic predictor of short-term remission: a meta-analysis of five clinical cohorts

    Article • International Clinical Psychopharmacology, December 2021, Wolters Kluwer Health

    Giuseppe Fanelli

  26. P.0882 A meta-analysis of polygenic risk scores for mood disorders, neuroticism, and schizophrenia in antidepressant response

    Article • European Neuropsychopharmacology, December 2021, Elsevier

    Giuseppe Fanelli

  27. W68. A META-ANALYSIS OF POLYGENIC RISK SCORES FOR MOOD DISORDERS, NEUROTICISM, AND SCHIZOPHRENIA IN ANTIDEPRESSANT RESPONSE

    Article • European Neuropsychopharmacology, October 2021, Elsevier

    Giuseppe Fanelli

  28. TH59. INSULINOPATHIES OF THE BRAIN? GENETIC OVERLAP BETWEEN SOMATIC INSULIN-RELATED AND NEUROPSYCHIATRIC DISORDERS

    Article • European Neuropsychopharmacology, October 2021, Elsevier

    Giuseppe Fanelli

  29. Gastrointestinal side effects associated with antidepressant treatments in patients with major depressive disorder: A systematic review and meta-analysis

    Article • Progress in Neuro-Psychopharmacology and Biological Psychiatry, July 2021, Elsevier

    Giuseppe Fanelli

  30. A meta-analysis of polygenic risk scores for mood disorders, neuroticism, and schizophrenia in antidepressant response

    Article • June 2021, Cold Spring Harbor Laboratory Press

    Giuseppe Fanelli

  31. Higher polygenic risk scores for schizophrenia may be suggestive of treatment non-response in major depressive disorder

    Article • Progress in Neuro-Psychopharmacology and Biological Psychiatry, June 2021, Elsevier

    Giuseppe Fanelli

  32. Insulinopathies of the brain? Genetic overlap between somatic insulin-related and neuropsychiatric disorders

    Article • May 2021, Cold Spring Harbor Laboratory Press

    Giuseppe Fanelli

  33. Polygenic risk scores for psychiatric, inflammatory, and cardio-metabolic traits and diseases highlight possible genetic overlaps with suicide attempt and treatment-emergent suicidal ideation

    Article • March 2021, Cold Spring Harbor Laboratory Press

    Giuseppe Fanelli

  34. P.169 Genetic overlap between somatic insulin-related and neuro-psychiatric disorders

    Article • European Neuropsychopharmacology, November 2020, Elsevier

    Giuseppe Fanelli

  35. P.171 Higher polygenic risk scores for schizophrenia may be suggestive of treatment non-response in major depressive disorder

    Article • European Neuropsychopharmacology, November 2020, Elsevier

    Giuseppe Fanelli

  36. P.179 Polygenic risk scores for multiple psychiatric, inflammatory and cardio-metabolic traits highlight possible genetic overlap with suicide attempt

    Article • European Neuropsychopharmacology, November 2020, Elsevier

    Giuseppe Fanelli

  37. Higher polygenic risk scores for schizophrenia may be suggestive of treatment non-response in major depressive disorder

    Article • January 2020, Cold Spring Harbor Laboratory Press

    Giuseppe Fanelli

  38. Reduced plasma Fetuin-A is a promising biomarker of depression in the elderly

    Article • European Archives of Psychiatry and Clinical Neuroscience, December 2019, Springer Science + Business Media

    Giuseppe Fanelli

  39. P.306 Reduced chemokine ligand 1/GRO chemokine plasma levels are a possible biomarker of elderly depression

    Article • European Neuropsychopharmacology, December 2019, Elsevier

    Giuseppe Fanelli

  40. M74 HIGHER POLYGENIC RISK SCORES FOR SCHIZOPHRENIA MAY BE SUGGESTIVE OF NON-RESPONSE TO DRUGS FOR DEPRESSION IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER

    Article • European Neuropsychopharmacology, October 2019, Elsevier

    Giuseppe Fanelli

  41. Reduced CXCL1/GRO chemokine plasma levels are a possible biomarker of elderly depression

    Article • Journal of Affective Disorders, April 2019, Elsevier

    Giuseppe Fanelli

  42. P.4.01 C-X-C chemokine signalling is implicated in major depressive disorder in a sample of Korean elderly subjects

    Article • European Neuropsychopharmacology, January 2019, Elsevier

    Giuseppe Fanelli

  43. SA92THE INFLUENCE OF THE SEROTONIN TRANSPORTER GENE 5-HTTLPR POLYMORPHISM ON SUICIDAL BEHAVIORS: A META-ANALYSIS

    Article • European Neuropsychopharmacology, January 2019, Elsevier

    Giuseppe Fanelli

  44. The influence of the serotonin transporter gene 5-HTTLPR polymorphism on suicidal behavior: a meta-analysis

    Article • European Neuropsychopharmacology, January 2019, Elsevier

    Giuseppe Fanelli

  45. The influence of the serotonin transporter gene 5-HTTLPR polymorphism on suicidal behaviors: a meta-analysis

    Article • Progress in Neuro-Psychopharmacology and Biological Psychiatry, January 2019, Elsevier

    Giuseppe Fanelli

  46. A Polygenic Risk Score of glutamatergic SNPs associated with schizophrenia predicts attentional behavior and related brain activity in healthy humans

    Article • European Neuropsychopharmacology, September 2017, Elsevier

    Giuseppe Fanelli